Showing results (201-210 of 215) with videos related to

Sort By:
Pageof 22
Journal of the American College of Surgeons|July 13, 2002
Locoregional recurrence and survival after curative resection of adenocarcinoma of the colonThomas E Read, Matthew G Mutch, Benjamin W Chang, et al.
Annals of Internal Medicine|December 28, 1999
Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancerB Cagir, A Gelmann, J Park, et al.
Diseases of the Colon and Rectum|March 26, 1998
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancerS A Waldman, B Cagir, J Rakinic, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2001
Pretreatment clinical findings predict outcome for patients receiving preoperative radiation for rectal cancerR J Myerson, A Singh, E H Birnbaum, et al.
Oncogene|May 9, 2017
Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitinationJ H Wald, J Hatakeyama, I Printsev, et al.
Cancer Research|July 15, 1991
Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trialS C Yang, E A Grimm, D R Parkinson, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2001
Treatment of rectal adenocarcinoma with endocavitary and external beam radiotherapy: results for 199 patients with localized tumorsA Aumock, E H Birnbaum, J W Fleshman, et al.
Oncology Reports|April 4, 1998
Effects of PALA on the pharmacokinetics of 5-fluorouracilM A Nassim, M R Rouini, M C Cripps, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131K A Gelmon, D Stewart, K N Chi, et al.
Molecular Cancer Research : MCR|August 9, 2011
Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancerSheryl R Krig, Seth Frietze, Catalina Simion, et al.
Pageof 22